about
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.Opportunities for immunotherapy in microsatellite instable colorectal cancerImproving cancer immunotherapy by targeting the STATe of MDSCsEarly identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defectImmune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Harnessing human plasmacytoid dendritic cells as professional APCs.In vivo tracking techniques for cellular regeneration, replacement, and redirection.Tumoricidal activity of human dendritic cells.Cell tracking using multimodal imaging.Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.Cell tracking using (19)F magnetic resonance imaging: technical aspects and challenges towards clinical applications.Scientific contributions toward successful cancer immunotherapy in The Netherlands.Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy.A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.Dendritic cell vaccination in melanoma patients: From promising results to future perspectivesType I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists.Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function.Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma.Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.Naturally circulating dendritic cells to vaccinate cancer patients.Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets.Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses.
P50
Q27323878-DF2FFE41-DCDA-4F89-A8F3-D2AFF8F37450Q28066110-CBB39D24-434D-4C25-9FA4-53C9AB990D93Q28066797-EC67A390-432D-43E6-8D4F-384EDF259B2AQ35546673-F7318BB3-E6D2-423E-9FB0-77E0A57DCAC5Q35887247-324711A2-F806-4472-82E9-4ABC13821C1DQ36597497-1318C1B0-4996-419A-A887-EC50B9E58272Q36597517-F0CDE9B1-5468-4CC4-A208-D6F9AD4D6721Q36717841-C80E4563-E790-466F-BA5F-674F12F8D701Q36992766-4B3122AB-94BC-41E5-BF5C-C19001BDE677Q37145706-05A9FB86-6464-4449-AE64-0A5435E0587AQ37222157-B27529BA-7321-474B-A169-4083A3B02750Q37224609-A36F2913-9732-4E45-8596-3F90A0122E1BQ37980404-9B74B4C4-556D-40A8-B81B-7DE7338F4AD8Q38059103-317F9151-2798-447A-AEF8-88F87698521BQ38164916-1F5904C8-C2BF-4833-858B-F19EB9D70191Q38174552-82DDFC38-B6EC-4374-B7B4-4DDAD9072229Q38208309-FEF650C5-1B12-4716-A183-26D2C2685094Q38212231-AA79F238-178E-4E87-8122-FF4B463460AFQ38216254-D9B0730D-98D1-48EB-9A76-5192FD8B2A17Q38265406-0E2B9037-6FF1-4D0D-91CA-4264585B3675Q38279505-79ED47E2-F991-45E4-B995-FA6F2F2735C9Q38281546-1342AA7D-64FD-4641-8AF6-445EDF686EECQ38322251-58A5B219-4E31-4AB7-B845-ADC83E6F24ADQ38365774-6AAB81EE-BC75-46CB-8803-3AD4133CCBDDQ38576179-F544382F-EE05-4CB5-9B23-45FC5BCA43D3Q38730777-40585CBC-7396-47A8-AF82-8098FAFCF5B1Q38809786-88E3FE7D-9758-4C85-B58C-F82176C5EBBDQ38850950-76DD7B3A-2013-410E-A8A1-FA19394CC133Q38976179-55811E64-7064-41CD-A5B8-BBA00A03F73AQ39281392-AA3254E3-2DBC-438D-A34A-851DE9FB3441Q39392060-5B7589FB-F18F-456D-BEBE-4683033D6E14Q39443969-62A1F959-A922-41E6-9A5B-1FDEE848B032Q39838078-795DA963-59C9-4CC6-AF95-9732D9AB79A0Q40155520-556A11E2-CC78-4864-B9C4-6D9E1A7DD9A0Q40745798-B881EE12-78FC-4403-B2FC-C595E7C1FCDAQ40930007-B7F8C0B5-8370-4E30-AF7D-4F99E3DD1548Q41343094-CD8AAFC2-834E-4BB8-9508-F3D59268D350Q41575936-445B0170-EF4F-4F29-8AA0-68777FE5FBC9Q41835523-775EBA6D-344E-427F-801F-B7F5E63ADEDFQ41933827-897D16FB-960B-423E-A39C-F778CF3ADA66
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jolanda de Vries
@ast
Jolanda de Vries
@en
Jolanda de Vries
@es
Jolanda de Vries
@nl
type
label
Jolanda de Vries
@ast
Jolanda de Vries
@en
Jolanda de Vries
@es
Jolanda de Vries
@nl
prefLabel
Jolanda de Vries
@ast
Jolanda de Vries
@en
Jolanda de Vries
@es
Jolanda de Vries
@nl
P106
P21
P31
P496
0000-0002-8653-4040